Dry-Eye Study Using RGN-259 Released
Topic: Eye Care
RegeneRx Biopharmaceuticals, Inc. "announced the results of its first non-clinical dry eye study using RGN-259, RegeneRx's ophthalmic, preservative-free eye drop for the treatment of Dry Eye Syndrome (DES). In the study, animals were treated with RGN-259, a vehicle control and a positive control, doxycycline. Corneal fluorescein staining was used to measure the surface defects after induction of DES using an industry accepted dry eye model. In animals treated with RGN-259, a "dramatic" and statistically significant reduction in corneal staining (p<0.03) was observed compared to those treated with the vehicle control and equivalent to original levels seen prior to induction of DES. The treatment effect using RGN-259 was also more pronounced than that observed with the positive control, an accepted treatment for dry eye and ocular surface inflammation,"according to a MarketWatchReport.